Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2013005921
pages 177-195

Causes of Death Due to Hematological and Non-Hematological Cancers in 57 US Patients with Type 1 Gaucher Disease Who Were Never Treated with Enzyme Replacement Therapy

Neal J. Weinreb
University Research Foundation for Lysosomal Storage Diseases, Boca Raton, Florida 33433, USA and the Dr. John T Macdonald Foundation, Department of Human Genetics at the University of Miami Miller School of Medicine, Miami, Florida, 33144, USA
Robert E. Lee
Department of Pathology (Emeritus), University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA

ABSTRAKT

Patients with type 1 Gaucher disease (GD1) have increased risk of developing myeloma, other hematological cancers, hepatocellular carcinoma, and other solid tumors. Patient awareness of the GD1–cancer association causes anxiety and fear. Little is known about cancer as a cause of death in GD1, especially in patients never treated with GD1-specific therapies. Consequently, the effect of treatment on cancer mortality in GD1 patients is difficult to evaluate. In this review, starting with a population of 184 GD1 cases never treated, we annotate and analyze the causes of death of 57 GD1 patients who died of cancer. The proportional mortality ratio (PMR) for all malignancies in patients with GD1 is 1.57 (p = 0.0002), but it is much higher for myeloma (PMR = 9.66) and other hematological cancers, hepatocellular carcinoma, and kidney cancer (PMR = ≈4). However, deaths from colorectal and pancreatic cancers were not more frequent than expected, and deaths from lung, breast, gynecological, and prostate cancer occurred less than anticipated. Herein, we discuss whether GD1 is truly a hereditary cancer syndrome and the problem of comorbidities and cancer risk assessment, and we speculate as to whether the variability in death by cancer type might be attributable to biochemical sequelae of tumor cell and macrophage/stromal cell GBA1 mutation affecting signals for metastasis, the process most closely associated with cancer mortality.


Articles with similar content:

Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Abdul Kareem Khan, Mamoon Ur Rashid, Ishtiaq Hussain, Sarfraz Ahmad, Asad Ur Rahman, Sundas Jehanzeb, Akriti Gupta Jain, Deepika Sarvepalli, Neelam Khetpal, Waqas Ullah, Badar Hasan
Lynch Syndrome and Related Familial Colorectal Cancers
Critical Reviews™ in Oncogenesis, Vol.14, 2008, issue 1
Paivi Peltomaki, Wael M. Abdel-Rahman
Nuclear Factor-κB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia
Critical Reviews™ in Oncogenesis, Vol.15, 2009, issue 1-2
Astrid Marta Olsnes, Elisabeth Ersvar, Oystein Bruserud, Bjorn Tore Gjertsen, Hakon Reikvam
Targeting the Insulin-like Growth Factor Receptor: Developing Biomarkers from Gene Expression Profiling
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
David N. Boone, Adrian V. Lee
Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society
Critical Reviews™ in Eukaryotic Gene Expression, Vol.24, 2014, issue 4
Ted James , Phil Brown, Jane Kolodinsky, Marie Wood, Christine Vatovec, Mujde Z. Erten, Brian L. Sprague